Monday, January 19, 2015

Reconnaître un cancer des glandes salivaires

Reconnaître un cancer des glandes salivaires

Les glandes salivaires sont de multiples petites entités qui ont pour rôle la fabrication de la salive.

Elles peuvent être l'objet de nombreuses affections : troubles de la fonction de sécrétion, lithiase, infection, voire cancer. Dans la majorité des cas, les tumeurs sont bénignes, mais peuvent parfois être malignes, ce qui concerne le plus souvent les glandes salivaires parotides.

La fonction des glandes salivaires est de produire la salive, laquelle sert à humidifier la bouche, participe à la digestion et à la santé buccodentaire.

Très nombreuses, les glandes salivaires se situent tout autour de la bouche. Il en existe trois types principaux :

les glandes parotides dans les joues, les glandes sous-maxillaires de chaque côté du cou, les glandes sublinguales sous la langue et de part et d'autre de la langue.

Chaque glande salivaire peut devenir cancéreuse, mais il s'agit le plus souvent des glandes parotides (85 % des cas de cancers des glandes salivaires). De croissance lente, la majorité des cancers des glandes salivaires sont bénins (75 à 80 % des cas). Ils ressemblent à de petits nodules mobiles dans la muqueuse buccale, ou à petits kystes fixes.
Lorsque les tumeurs sont malignes (20 à 25% des cas), leur croissance est rapide et imprévue. Les nodules sont alors durs et fixes.

L'hérédité (facteur génétique).L'environnement, notamment la pollution atmosphérique.Le tabagisme.La radiothérapie de la tête ou du cou.L'exposition professionnelle à des agents cancérigènes (nickel, silice, kérosène...).Un antécédent de cancer de la peau.L'usage de produits colorants pour les cheveux.Une consommation élevée de légumes conservés dans le sel.L'usage intensif du téléphone portable sans oreillettes.

Les symptômes d'un cancer des glandes salivaires peuvent être :

Des douleurs dans la bouche.Une ulcération de la muqueuse recouvrant la tumeur.Une perte de mouvement du visage.La présence de tumeurs dans le cou.Une masse non douloureuse dans le palais, les lèvres ou à l'intérieur de la bouche.Une obstruction ou une congestion nasale.Un changement de la vision.Dans tous les cas, il faut consulter votre médecin traitant, lequel est parfois amené à conseiller un ORL ou un spécialiste maxillo facial si vous présentez ces symptômes, mais aussi si vous repérez un ou des nodules durs et fixes dans votre bouche et particulièrement au niveau des joues.

Mis à jour par Isabelle Eustache le 18/09/2014
Créé initialement par Isabelle Eustache le 01/03/2010 Sources : Société française de stomatologie et chirurgie maxillo faciale, www.sfscmf.fr.


View the original article here

Thursday, October 9, 2014

Waistline Exercises - How in order to Lower your Waist

Everyone has a different name to call this specific part of the physique. Whether they'd label that as the waist, obliques, love handles, or boule tops. In the conclusion, it all means a single thing - a huge problem on your tummy!

Love grips and a large waist will be caused by a build-up of too much excess fat over the sides of typically the stomach and core. Which often means to reduce typically the waistline, some of typically the best waist exercises an individual can do -- usually are even "waist exercises" from all! Because to notice any results from carrying out those waist exercises, you must:

Eat Clean

View the original article here

Wednesday, October 8, 2014

Smoking cessation: how to prevent weight gain?

Smoking lose weight and the weight plug which followed the judgment of tobacco is generally as a catch-up, which incidentally is not inevitable...


How prevent weight gain to stop smoking?


The smoker is under-weight and generally wants to keep it when he decides to quit.


The smoking cessation weight gain is averaged 2.8 kg in males and 3.8 kg for women. However, number of ex-smokers take more, and conversely, number of smokers do not take, or even lose.


The power of the smoker is different from a non-smoker. And the food choices of the smoking increase the deleterious effect of the components of smoke on risk of cardiovascular disease and cancer...


Overall, smokers consume more calories than non-smokers, fat saturated fat, cholesterol and alcohol. On the other hand, they eat less polyunsaturated fat, omega-3 type, which are beneficial to health, fiber, vitamin C, vitamin E and beta carotene.


More muscle in smokers
Nicotine has hormonal effects favouring the key. Otherwise said, the muscle mass of smokers is more important and they manifest an increased protein requirement. The smoker has a specific appetite for protein.


But if the meat is the main source of protein, it also brings amount of saturated fat. In addition, suffering from a loss of taste and smell, smoker eat them in sauce and adding salt to promote the release of aromas. So a smoker consumes two times more salt than a non-smoker!


The other consequences of the loss of taste in the smoker
Also to put on the account of the decrease in its olfacto-gustatory sensitivity, the smoker eat few vegetables and fruits, it finds tasteless, tasteless. His spontaneous regime is therefore rich in saturated fat and salt, and low in fiber and micronutrients. It contributes to the prevalence of cardiovascular disease and certain cancers.


The smoker is also a sur-consommateur of alcohol, partly for an increase in energy harvest. And finally, the smoker uses more coffee and tea which he sugar more than others. In fact, it eliminates two times faster caffeine.

The IUD in 10 questions

The IUD is a contraception very effective and beneficial.


It is badly named since it causes no sterility and it can even be asked in a young woman who subsequently wishes to have children. This is why doctors prefer its other name, the intrauterine device, IUD.


The IUD is a small T-shaped device that is inserted into the uterus, from which its other name of intrauterine device (IUD). Some are copper, others are hormonal, meaning that they are equipped with a small tank that streams a hormone progestin (levonorgestrel).


How does it work?


Both types of devices make it inactive sperm, which prevents any fertilization.


Are all women they affected?


Yes, the IUD is aimed at all women, same young women and even to those who have not yet had children and will want later. After removal of the IUD, the return to fertility is immediate. Can be a baby on the way from the month following the withdrawal.

Tuesday, March 12, 2013

Baby’s HIV cured through treatment

CHICAGO - 
A baby girl in Mississippi who was born with HIV has been cured after very early treatment with standard drug therapy, U.S. researchers reported on Sunday, in a potentially ground-breaking case that could offer insights on how to eradicate HIV infection in its youngest victims.
The child’s story is the first account of an infant achieving a so-called functional cure, a rare event in which a person achieves remission without the need for drugs and standard blood tests show no signs that the virus is making copies of itself.
More testing needs to be done to see if the treatment would have the same effect on other children, but the results could change the way high-risk babies are treated and possibly lead to a cure for children with HIV, the virus that causes AIDS.
“This is a proof of concept that HIV can be potentially curable in infants,” said Dr. Deborah Persaud, a virologist at Johns Hopkins University in Baltimore, who presented the findings at the Conference on Retroviruses and Opportunistic Infections in Atlanta.
The child’s story is different from the now famous case of Timothy Ray Brown, the so-called “Berlin patient,” whose HIV infection was completely eradicated through an elaborate treatment for leukemia in 2007 that involved the destruction of his immune system and a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection.
Instead of Brown’s costly treatment, the Mississippi baby’s case involved the use of a cocktail of widely available drugs already used to treat HIV infection in infants.
When the baby girl was born in a rural hospital, her mother had just tested positive for HIV infection. Because her mother had not received any prenatal HIV treatment, doctors knew the child was born at high risk of being infected. So they transferred the baby to the University of Mississippi Medical Center in Jackson, where she came under the care of Dr. Hannah Gay, a pediatric HIV specialist.
Because of her high infection risk, Dr. Gay put the infant on a cocktail of three standard HIV-fighting drugs when she was just 30 hours old, even before lab tests came back confirming her infection. In more typical pregnancies when an HIV-infected mother has been given drugs to reduce the risk of transmission to her child, the baby would only have been given a single drug to reduce her infection risk.
Researchers believe this early use of antiviral treatment likely resulted in the infant’s cure by keeping the virus from forming hard-to-treat pools of cells known as viral reservoirs, which lie dormant and out of the reach of standard medications. These reservoirs rekindle HIV infection in patients who stop therapy, and they are the reason most HIV-infected individuals need lifelong treatment to keep the infection at bay.
10-MONTH GAP
After starting on treatment, the baby’s immune system responded and tests showed levels of the virus were diminishing until it was undetectable 29 days after birth. The baby received regular treatment for 18 months, but then stopped coming to appointments for a period of about 10 months, when her mother said she was not given any treatment. The doctors did not say why the mother stopped coming.
When the child came back under the care of Dr. Gay, she ordered standard blood tests to see how the child was faring before resuming antiviral therapy.
What she found was surprising. The first blood test did not turn up any detectible levels of HIV. Neither did the second. And tests for HIV-specific antibodies - the standard clinical indicator of HIV infection - also remained negative.
“At that point, I knew I was dealing with a very unusual case,” Dr. Gay said.
Baffled, Dr. Gay turned to her friend and longtime colleague, Dr. Katherine Luzuriaga of the University of Massachusetts, and she and Persaud did a series of sophisticated lab tests on the child’s blood.
The first looked for silent reservoirs of the virus where it remains dormant but can replicate if activated. That is detected in a type of immune cell known as a CD4 T-cell. After culturing the child’s cells, they found no sign of the virus.
Then, the team looked for HIV DNA, which indicates that the virus has integrated itself into the genetic material of the infected person. This test turned up such low levels that it was just above the limit of the test’s ability to detect it.
The third test looked for bits of genetic material known as viral RNA. They only found a single copy of viral RNA in one of the two tests they ran.
Because there is no detectible virus in the child’s blood, the team has advised that she not be given antiretroviral therapy (ART), whose goal is to block the virus from replicating in the blood. Instead, she will be monitored closely.
Dr. Rowena Johnston, vice president and director of research for the Foundation for AIDS Research, which helped fund the study, said the fact that the cure was achieved by antiretroviral therapy alone makes it “imperative that we learn more about a newborn’s immune system, how it differs from an adult’s and what factors made it possible for the child to be cured.”
Because the child’s treatment was stopped, the doctors were able to identify that this child had been cured, raising questions about whether other children who received early treatment and have undetectable viral loads may also be cured without knowing it.
But the doctors warned parents not to be tempted to take their children off treatment to see if the virus comes back. Normally, when patients stop taking their medications, the virus comes roaring back, and treatment interruptions increase the risk that the virus will develop drug resistance.
“We don’t want that,” Dr. Gay said. “Patients who are on successful therapy need to stay on their successful therapy until we figure out a whole lot more about what was going on with this child and what we can do for others in the future.”
The researchers are trying to find biomarkers that would offer a rationale to consider stopping therapy within the context of a clinical trial. If they can learn what caused the child to clear her virus, they hope to replicate that in other babies, and eventually learn to routinely prevent infections.
Thursday, March 7, 2013
Yes

No

Unsure

View the original article here

Monday, March 11, 2013

Doctor's 'gutsy' move led to baby's HIV cure

The doctor who cured an HIV infected baby for the first time is happier talking to children than to adults and is finding all the attention since the news came out a little overwhelming.
Dr. Hannah Gay and colleagues Dr. Katherine Luzuriaga of the University of Massachusetts and Dr. Deborah Persaud of Johns Hopkins University in Baltimore reported on the child's case at a medical meeting in Atlanta on Sunday.
"The breakthrough has been exciting and I'm very hopeful that that's going to lead to future research that will give us some answers," said Gay, a Mississippi pediatrician and soft-spoken mother of four adult children.
"This was a gutsy call that turned out to be correct."
- Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases
But the attention is difficult for a woman "much more comfortable talking to children than adults," said her husband, Paul Gay. "She didn't anticipate this kind of explosion of attention."
Dr. Gay, a 59-year-old native of Jackson, Mississippi, likes to spend time designing needle points, singing in her church choir and reading theology or medical literature when she's not working 12-hour days treating patients, in a state with the nation's highest poverty rate.
"She is the most unlikely person in the world to be getting this kind of international attention, really," said Jay Richardson, her former pastor at the Highland Colony Baptist Church. "You don't ever hear her talking about herself or trying to promote herself in any way. She's a quiet, humble person. Extremely intelligent. Very committed to her faith. Very involved in her church. Very committed to teaching children the bible."
Except for six years working in Ethiopia as a missionary, Dr. Gay has spent the bulk of her academic and professional career at the University of Mississippi, where she received her undergraduate and medical degrees and met her husband of 37 years. She has worked the better part of her career at the university's medical center serving the state's youngest victims of HIV.
During that time, Dr. Gay has published several articles about ways to keep mothers from passing HIV infection to their babies and participated in the federally sponsored Pediatric AIDS Clinical Trials Group, which studied the use of the aggressive treatment of children who are at high risk of infection.
Her daughter Ruth Gay Thomas says as an AIDS specialist her mother has had to fight the battles of her patients, overcoming access to healthcare and the stigma that comes along with being infected with HIV in the United States.
"She practices compassion and huge, unimaginable amounts of patience with her patients and their families," Thomas said. "She really has to embody a whole lot more than just the smart doctor that knows the right medications to give."
To treat her own rheumatoid arthritis, Dr. Gay takes medicine that affects her immune system. "She has that in common with her patients, but it's been a problem because with her compromised immune system, she can't have as much of a hands-on touching of her patients that was always so satisfying for her," her husband said.
When a rural hospital in Mississippi delivered a premature baby girl in July 2010 from a mother who had just tested positive for HIV during labor, it was only natural that they would turn to Dr. Gay. The child's mother had not received any prenatal care, nor had she gotten any treatment for her HIV infection, putting the baby at high risk of becoming infected.
Dr. Gay chose to start the baby on the full treatment regimen of three potent drugs when she was just 30 hours old, even before the child's infection was confirmed.
It was a bold move. Most babies exposed to HIV in the womb or during labor would have been given a six-week course of one or two drugs intended to reduce the risk of acquiring infection until tests could confirm she was infected.
"The doctor made a judgment call that the risks for this baby were so high that they were going to assume the baby was infected," said Dr. Anthony Fauci, director of the National Institutes of Allergy and Infectious Diseases, a part of the National Institutes of Health or NIH.
Some critics have questioned Dr. Gay's decision, which may have exposed the child to the risk of toxic medications without confirmation of her infection.
"This was a gutsy call that turned out to be correct," said Fauci, adding that if it had turned out that the baby was not infected, they could have withdrawn the drugs. "They made the right guess."
Dr. Gay continued to treat the child until January 2012, when she was 18 months old and her mother stopped bringing the child in for appointments. Gay's team tracked her down in the fall of 2012, but the mother had not given her child any HIV medication since January.
Before restarting treatment, Gay did several tests, fully expecting that the virus had come roaring back. But none of the tests detected the virus. That's when she brought in colleagues Luzuriaga of the University of Massachusetts and Persaud of Johns Hopkins University in Baltimore, who did a series of ultrasensitive tests. They were only able to find trace amounts of genetic material from the virus, but nothing capable of rekindling the infection.
The child, now 30 months old, remains off medication and continues to fare well. "We can't find any virus to treat at this point," Dr. Gay said.
She said it is not clear what the child's story will mean in the wider scheme of HIV research, but she hopes it may lead to a cure for other babies infected at birth.
"I guess the message that I want to get across to the public very strongly is, we don't know yet if we can create the same outcome in other babies." she said. "It's far too early to draw too many conclusions. There's not a cure in sight this week."
Dr. Gay said she is glad that this is happening in Mississippi and hopes it boosts the state's reputation.
"But it's a whole lot bigger than this one child, the University Medical Center or the state," she said. "It may take a long time, but I hope it will point us in the right direction to come up with a cure we can consistently apply to other babies worldwide."
Colleagues at the medical center are planning a celebration for Dr. Gay to "let her know how proud we are," said Amy Smith, a nurse practitioner who works with the doctor. "She's the type that wouldn't want a big fuss made about her, but we're going to do it anyway."

View the original article here

HIV Baby 'Cure' Has Ties To Elizabeth Glaser Pediatric AIDS Foundation In Los Angeles

LOS ANGELES -- When doctors announced that a Mississippi toddler born with HIV was functionally cured, the news sent shockwaves around the globe.

But the medical marvel hit close to home for a few residents in Los Angeles -- friends and associates of the late AIDS activist Elizabeth Glaser. Glaser lost her battle with AIDS 19 years ago, but the work she began to eradicate pediatric AIDS worldwide can still be felt through the Elizabeth Glaser Pediatric AIDS Foundation, a nonprofit research organization she founded after her daughter succumbed to AIDS in 1988. In fact, her legacy is imprinted on the so-called Mississippi miracle.

Two doctors involved in the Mississippi toddler's case are recipients of the Elizabeth Glaser Scientist Awards, generous five-year grants of $700,000 that Glaser's foundation gave to leaders in the field of pediatric AIDS research from 1996 to 2006.

Dr. Deborah Persaud of Johns Hopkins Children's Center received the Elizabeth Glaser Scientist Award in 2005. She led the investigation to determine that the toddler's HIV virus was in remission. She conducted the investigation with Dr. Katherine Luzuriaga of the University of Massachusetts Medical School, who was an award recipient in 1997.

The connection to the Mississippi medical case makes Susie Zeegen, one of Elizabeth Glaser Pediatric AIDS Foundation's co-founders, immensely proud.

"We were investing in people, and the people that got this award were above and beyond in their zeal and their promise to be able to come up with new and innovative approaches to the probems that children face," said Zeegen in an interview with The Huffington Post on Tuesday. "I'm sure [Glaser] would be beyond proud and happy as am I."

Zeegen is still awestruck at the apparent "cure." Since news about the toddler broke on Sunday, she has been busy collecting every single article written about the baby. She could only think of one word to describe her reaction: "Wow."

"My overall reaction is of great joy and great optimism," Zeegen said. And in the global fight to eradicate pediatric AIDS, a little bit of optimism couldn't hurt. Currently, an estimated 600,000 babies are born each year with HIV worldwide.

But because of her decades of work with Elizabeth Glaser Pediatric AIDS Foundation, Zeegen is cautious about forecasting what the toddler's cure may mean for pediatric AIDS worldwide.

"What happened in Mississippi is an impetus to get us all charged up again about being able to really and truly eradicate HIV from children," Zeegen said. "There's a ton of work that has to happen, and we all know that."

Chip Lyons, president and CEO of the Elizabeth Glaser Pediatric AIDS Foundation, echoed Zeegen's enthusiasm and caution.

"The case needs to be very carefully examined," said Lyons. The foundation is focusing on cutting rates of perinatal HIV infection around the globe, especially in India and countries in sub-Saharan Africa. Lyons, based in Washington, couldn't help but give part of the credit for this global movement to Los Angeles, Glaser's home.

"Philanthropists, donors, friends, and particularly the LA community -- there was a remarkable rallying around their friend, who was still fighting for herself, fighting for her son, and fighting to get kids on the agenda," said Lyons.

Glaser founded the organization in 1988 after the death of her 7-year-old daughter, Ariel. When Glaser gave birth to Ariel in 1981, she unknowingly contracted HIV from a blood transfusion and then passed on the disease to Ariel through breastfeeding. Her son, Jake, also subsequently contracted HIV in utero. It wasn't until Ariel started suffering unexplained symptoms that doctors determined all three of them had HIV.

After Ariel died, Glaser was determined to save her son from the same fate. Together with the help of friends Zeegen and Susan Delaurentis, Glaser mined her Hollywood industry contacts (her husband was actor/director Paul Michael Glaser) to raise money and awareness about pediatric AIDS during a time that researchers weren't studying HIV-affected families or pediatric formulations of drug treatments. Now Elizabeth Glaser Pediatric AIDS Foundation has offices in 15 countries and is working on a global scale to bring down the rates of perinatal HIV transmission.

Get Alerts

View the original article here